Stocks · News reference
AEON Biopharma Q2 EPS $(0.02) Beats $(0.12) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.12) by 83.33 percent. This is a 96.67 percent increase over losses of $(0.60) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why AeroVironment Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
AeroVironment surged 5.8% premarket after beating Q1 revenue and EPS estimates; Synergy CHC led gainers, while Ribbon Acquisition fell.
AEON Biopharma Says Pilot Forced Degradation Study Showed ABP-450 And AbbVie's BOTOX Lost Potency At Comparable Rates Under Thermal Stress, Similar Methionine Oxidation Patterns; Plans Multi-Lot Comparability Study In H1 2027
AEON Biopharma Designates Paul Lee As Chief Regulatory Office